GILOTRIF^®

About GILOTRIF^®

1. Marketed by Boehringer Ingelheim Pharmaceuticals, Inc
2. Orally bioavailable anilino-quinazoline derivative and inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family
3. First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations

Approvals

1. First U.S. approval: July 12, 2013
2. First E.U. approval: September 25, 2013

Constraint date forecast:

1. Patent expiry: 2026 (United States)
2. SPC expiry: 2026 (European Union)
3. Patent expiry: 2026 (Japan)

API availability

Source: Cortellis Generics Intelligence